PR Newswire
BRIDGEWATER, N.J., Feb. 22, 2024
—Topline Data from the Phase 3 ASPEN Trial of Brensocatib in Adult Patients with Bronchiectasis Remain on Track to Read Out in the Latter Part of Second-Quarter 2024—
—Enrollment in the Phase 2 Study of TPIP in Patients with PH-ILD Completed in November 2023; Topline Data Expected in Second-Quarter 2024 Ahead of the ASPEN Readout—
—Company Ends 2023 With $780 Million of Cash, Cash Equivalents, and Marketable Securities, Providing Runway Beyond the Expected ASPEN Readout—
— ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $83.7 Million for Fourth-Quarter and $305.2 Million for Full-Year 2023, Reflecting 24% Annual Growth and Exceeding the Upper End of Full-Year 2023 Guidance Range—
—Company Reiterates Sales Guidance for 2024 Global ARIKAYCE Revenues in the Range of $340 Million to $360 Million, Reflecting Double-Digit Growth Compared to 2023—
BRIDGEWATER, N.J., Feb. 22, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
"Insmed continued to deliver strong performance in 2023, demonstrating commercial success evidenced by ARIKAYCE revenues that exceeded the upper end of our 2023 sales guidance range," said Will Lewis, Chair and Chief Executive Officer of Insmed. "The positive ARISE data announced in September 2023, followed by encouraging blinded TPIP data shortly thereafter, marked the beginning of a transformative period of clinical catalysts for the Company. This series of meaningful data readouts from our mid- to late-stage pipeline is expected to continue uninterrupted in the months ahead, with topline results from the PH-ILD and ASPEN trials expected in quick succession in the second quarter. We believe these near-term data readouts have the potential to fundamentally change the trajectory for our company and the patients we serve."
Recent Pillar Highlights
Pillar 1: ARIKAYCE
Pillar 2: Brensocatib
Pillar 3: TPIP
Pillar 4: Early-Stage Research
Fourth-Quarter and Full-Year 2023 Financial Results
Balance Sheet, Financial Guidance, and Planned Investments
(i) commercialization and expansion of ARIKAYCE globally;
(ii) advancement of brensocatib, including the Phase 3 ASPEN study in patients with bronchiectasis, and commercial launch readiness activities, the ongoing Phase 2 trial in patients with CRSsNP, and the Phase 2 program in HS to be initiated in the second half of the year if the ASPEN result is positive;
(iii) advancement of the clinical trial program for ARIKAYCE, which is intended to satisfy the post-marketing requirement for full approval of its current indication and potentially support label expansion to include all patients with a MAC lung infection;
(iv) advancement of its Phase 2 clinical development programs for TPIP; and
(v) development of its early-stage research programs.
Conference Call
Insmed will host a conference call beginning today at 8:30 AM Eastern Time. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S. and international) and referencing access code 7862189. The call will also be webcast live on the Company's website at www.insmed.com.
A replay of the conference call will be accessible approximately 1 hour after its completion through March 23, 2024, by dialing (800) 770-2030 (U.S. and international) and referencing access code 7862189. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at www.insmed.com.
INSMED INCORPORATED | | |||||||
Consolidated Statements of Net Loss | | |||||||
(in thousands, except per share data) | | |||||||
(unaudited) | | |||||||
| | | | | | | | |
| Three Months Ended | | Twelve Months Ended | | ||||
| 2023 | | 2022 | | 2023 | | 2022 | |
| | | | | | | ||
Product revenues, net | $ 83,693 | | $ 59,300 | | $ 305,208 | | $ 245,358 | |
| | | | | | | | |
Operating expenses: | | | | | | | | |
Cost of product revenues (excluding amortization of intangible assets) | 18,443 | | 13,069 | | 65,573 | | 55,126 | |
Research and development | 137,029 | | 124,763 | | 571,011 | | 397,518 | |
Selling, general and administrative | 89,530 | | 73,479 | | 344,501 | | 265,784 | |
Amortization of intangible assets | 1,263 | | 1,264 | | 5,052 | | 5,053 | |
Change in fair value of deferred and contingent consideration liabilities | 15,700 | | (1,800) | | 28,697 | | (20,802) | |
Total operating expenses | 261,965 | | 210,775 | | 1,014,834 | | 702,679 | |
| | | | | | | | |
Operating loss | (178,272) | | (151,475) | | (709,626) | | (457,321) | |
| | | | | | | | |
Investment income | 9,853 | | 8,318 | | 42,132 | | 11,081 | |
Interest expense | (20,784) | | (16,445) | | (81,694) | | (26,446) | |
Change in fair value of interest rate swap | 1,970 | | (1,526) | | 320 | | (1,526) | |
Other income (expense), net | 2,170 | | 1,130 | | 1,856 | | (5,939) | |
Loss before income taxes | (185,063) | | (159,998) | | (747,012) | | (480,151) Werbung Mehr Nachrichten zur Insmed Inc Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE (Mit der Bestellung akzeptierst du die Datenschutzhinweise) -1 Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink. Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte. |